
Diabetic Neuropathic Pain Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
Description
Diabetic Neuropathic Pain Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
Summary
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the diabetic neuropathic pain market through 2031.
Diabetic neuropathic pain (DNP) is clinically defined as pain resulting from peripheral, autonomic, focal, or proximal nerve damage in patients with diabetes mellitus (DM). It most commonly manifests distally to affect the hands and feet and can occur in patients with either a type 1 diabetes (T1D) or type 2 diabetes (T2D) diagnosis. Symptoms vary from tingling, burning, sharp, shooting, or lancinating pain.
Growth in the DNP market is expected to be driven by the potential introduction of four promising late-stage pipeline products into the market during the forecast period, some of which are directed towards significant unmet needs
Key Highlights
Summary
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the diabetic neuropathic pain market through 2031.
Diabetic neuropathic pain (DNP) is clinically defined as pain resulting from peripheral, autonomic, focal, or proximal nerve damage in patients with diabetes mellitus (DM). It most commonly manifests distally to affect the hands and feet and can occur in patients with either a type 1 diabetes (T1D) or type 2 diabetes (T2D) diagnosis. Symptoms vary from tingling, burning, sharp, shooting, or lancinating pain.
Growth in the DNP market is expected to be driven by the potential introduction of four promising late-stage pipeline products into the market during the forecast period, some of which are directed towards significant unmet needs
Key Highlights
- Forecasts includes the 7MM
- Forecasts covers from 2021-2031
- In the 7MM, the diagnosed prevalent cases of DNP will increase from 4,447,050 cases in 2021 to 5,157,455 cases in 2031, at an AGR of 1.60%.
- The current DNP treatment landscape includes many established analgesics that provide symptomatic relief. The main drug classes that are used l include tricyclic antidepressants (TCAs), serotonin and noradrenaline reuptake inhibitors (SNRIs), alpha-2-delta ligands (gabapentinoids), sodium channel blockers, and topical treatments.
- The DNP market will exhibit moderate growth between 2021 and 2031, driven by the entry of four pipeline agents.
- Engensis will be welcomed by patients as the underlying pathophysiology of DNP will be targeted, rather than symptomatic treatment.
- Overview of diabetic neuropathic pain, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized diabetic neuropathic pain therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the diabetic neuropathic pain therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for diabetic neuropathic pain treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
- Analysis of the current and future market competition in the global diabetic neuropathic pain therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global diabetic neuropathic pain therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global diabetic neuropathic pain therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
Table of Contents
127 Pages
- 1 Diabetic Neuropathic Pain: Executive Summary
- 1.1 DNP market will grow to $3.0 billion
- 1.2 Key players will struggle to maintain their competitive position
- 1.3 While outlook in DNP improves, opportunities remain to improve patient outcomes
- 1.4 Novel late-stage pipeline drugs will be a key driver of growth
- 1.5 What do physicians think?
- 2 Introduction
- 2.1 Catalyst
- 2.2 Related reports
- 2.3 Upcoming reports
- 3 Disease Overview
- 3.1 Etiology and pathophysiology
- 3.1.1 Etiology
- 3.1.2 Pathophysiology
- 3.2 Classification or staging systems
- 4 Epidemiology
- 4.1 Disease background
- 4.2 Risk factors and comorbidities
- 4.3 Global and historical trends
- 4.4 7MM forecast methodology
- 4.4.1 Sources used
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Total prevalent cases of DNP
- 4.4.4 Diagnosed prevalent cases of DNP
- 4.4.5 Diagnosed prevalent cases of DNP by DSPN and non-DSPN
- 4.4.6 p-DPN among diagnosed prevalent cases of T1D and T2D
- 4.5 Epidemiological forecast for total prevalent cases of DNP (2021–31)
- 4.5.1 Total prevalent cases of DNP
- 4.5.2 Age-specific total prevalent cases of DNP
- 4.5.3 Sex-specific total prevalent cases of DNP
- 4.5.4 Diagnosed prevalent cases of DNP
- 4.5.5 Diagnosed prevalent cases of DNP by DSPN and Non-DSPN
- 4.5.6 p-DPN among diagnosed prevalent cases of T1D and T2D
- 4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 COVID-19 impact
- 4.6.3 Limitations of the analysis
- 4.6.4 Strengths of the analysis
- 5 Disease Management
- 5.1 Diagnosis overview
- 5.2 Treatment overview
- 5.3 Other KOL insights on disease management
- 6 Competitive Assessment
- 6.1 Overview
- 7 Unmet Needs and Opportunity Assessment
- 7.1 Overview
- 7.2 Development of therapies with an improved efficacy profile
- 7.3 Development of therapies with improved safety and tolerability profile
- 7.4 Development of a curative or disease-modifying agent
- 7.5 Improving physician and public recognition of DNP
- 8 R&D Strategies
- 8.1 Overview
- 8.1.1 Development of analgesics with novel MOAs
- 8.1.2 Patient stratification
- 8.2 Clinical trials design
- 8.2.1 Clinical endpoints
- 8.2.2 High failure rate in DNP clinical trials
- 8.2.3 Patient recruitment
- 9 Pipeline Assessment
- 9.1 Overview
- 9.2 Promising drugs in clinical development
- 10 Pipeline Valuation Analysis
- 10.1 Overview
- 10.2 Competitive assessment
- 11 Current and Future Players
- 11.1 Overview
- 11.2 Deal-making trends
- 12 Market Outlook
- 12.1 Global markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers – global issues
- 12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
- 12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
- 12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and barriers
- 13 Appendix
- 13.1 Bibliography
- 13.2 Abbreviations
- 13.3 Methodology
- 13.3.1 Forecasting methodology
- 13.4 Primary research – KOLs interviewed for this report
- 13.4.1 KOLs
- 13.5 Primary research – prescriber survey
- 13.6 About the Authors
- 13.6.1 Analyst
- 13.6.2 Therapy Area Director
- 13.6.3 Epidemiologist
- 13.6.4 Managing Epidemiologist
- 13.6.5 Vice President of Disease Analysis and Intelligence
- 13.6.6 Global Head and EVP of Healthcare Operations and Strategy
- Contact Us
- List of Tables
- Table 1: DNP: key metrics in the 7MM
- Table 2: Classification of diabetic neuropathies
- Table 3: Risk factors and comorbid conditions associated with DNP
- Table 4: Treatment Guidelines for DNP
- Table 5: DNP market – global drivers and barriers, 2021–2031
- Table 6: Key events impacting sales for DNP in the US, 2021–2031
- Table 7: DNP market – drivers and barriers in the US, 2021–2031
- Table 8: Key events impacting sales for DNP in the 5EU, 2021–2031
- Table 9: DNP market – drivers and barriers in the 5EU, 2021–2031
- Table 10: Key events impacting sales for DNP in Japan, 2021–2031
- Table 11: DNP market – drivers and barriers in Japan, 2021–2031
- Table 12: High-prescribing physicians (non-KOLs) surveyed, by country
- List of Figures
- Figure 1: Global sales forecast by country for DNP in 2021 and 2031
- Figure 2: Analysis of the company portfolio gap in DNP during the forecast period
- Figure 3: Competitive assessment of the pipeline drugs benchmarked against the SOC, Lyrica (pregabalin)
- Figure 4: Pain pathway – somatosensory system
- Figure 5: The pathogenesis of diabetic neuropathy is multifactorial
- Figure 6: 7MM, total prevalence of DNP (%), men and women, ages ≥20 years, 2021
- Figure 7: 7MM, diagnosed prevalence of DNP (%), men and women, ages ≥20 years, 2021
- Figure 8: Case flow map
- Figure 9: 7MM, sources used to forecast the total prevalent cases of DNP
- Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of DNP
- Figure 11: 7MM, sources used to forecast the diagnosed prevalent cases of DNP by DSPN and non-DSPN
- Figure 12: 7MM, sources used to forecast p-DPN by T1D and T2D
- Figure 13: 7MM, total prevalent cases of DNP, N, men and women, ages ≥20 years, 2021
- Figure 14: 7MM, total prevalent cases of DNP by age, N, men and women, 2021
- Figure 15: 7MM, total prevalent cases of DNP by sex, N, ages ≥20 years, 2021
- Figure 16: 7MM, diagnosed prevalent cases of DNP, N, men and women, ages ≥20 years, 2021
- Figure 17: 7MM, diagnosed prevalent cases of DNP by DSPN and non-DSPN, N, men and women, ages ≥20 years, 2021
- Figure 18: 7MM, p-DPN among diagnosed prevalent cases of T1D and T2D, N, men and women, ages ≥20 years, 2021
- Figure 19: General treatment algorithm for DNP
- Figure 20: Unmet needs and opportunities in DNP
- Figure 21: Overview of the development pipeline in DNP
- Figure 22: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for DNP in the 7MM during the forecast period
- Figure 23: Competitive assessment of the pipeline drugs benchmarked against the SOC, Lyrica (pregabalin)
- Figure 24: Analysis of the company portfolio gap in DNP during the forecast period
- Figure 25: Global (7MM) sales forecast by country for DNP in 2021 and 2031
- Figure 26: Sales forecast by class for DNP in the 7MM in 2021 and 2031
- Figure 27: Sales forecast by class for DNP in the US in 2021 and 2031
- Figure 28: Sales forecast by class for DNP in the 5EU in 2021 and 2031
- Figure 29: Sales forecast by class for DNP in Japan in 2021 and 2031
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.